

Errata to the FDA Briefing Document  
Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM)  
and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)  
May 3-4, 2016

Extended-release and Long-acting (ER/LA) Opioid Analgesics Risk Evaluation and  
Mitigation Strategy (REMS)

Note: Page numbers reflect the numbers at page bottom within each document.

**FDA Errata to Appendix 5: List of Approved ER/LA Opioid Analgesic Products**

Page	Description of Error with Correction
290	Application holder for Kadian, Application number 20616 should read: Allergan
290	Application holder for Nucynta ER, Application number 200533 should read: Depomed
290	Application holder for Zohydro, Application number 202880 should read: Pernix